In vitro activity of imipenem–relebactam against carbapenem-resistant Pseudomonas aeruginosa: correlation with carbapenem MICs and association with β-lactamase classes
Ali M. Somily
IntroductionCarbapenem-resistant P. aeruginosa (CRPA) poses a major therapeutic challenge due to the limited number of available treatment options. Imipenem-relebactam (IMP-REL), a carbapenem combined with a Class A/C β-lactamase inhibitor, has demonstrated activity against selected multidrug-resistant isolates. This retrospective, observational, analytical, laboratory-based study represents one of the early reports from Saudi Arabia and the Middle East and North Africa (MENA) region evaluating